Jingshan Tong, PhD

Research Instructor

Hillman Cancer Center, 5117 Centre Avenue Research Pavilion, Lab 2.43
Pittsburgh, PA 15232
Phone: 412-623-3255
Fax: 412-623-7778

Education

BS (Laboratory Diagnosis Medicine), Dalian Medical University, China, 2004
MS (Inorganic Chemistry), Changchun University of Science and Technology, China, 2008
PhD (Cell Biology), Jilin University, China, 2011
 
Jingshan Tong, PhD
Mcl-1, a prosurvival Bcl-2 family protein, is often degraded in cancer cells subjected to effective therapeutic treatment, and defective Mcl-1 degradation has been associated with intrinsic and acquired drug resistance. Dr. Tong’s findings established a pivotal role for Mcl-1 degradation in the response of colon cancer cells to target therapeutics. Dr. Tong also revealed a novel degradation–independent function of Mcl-1 phosphorylation in anticancer therapy that could be useful for developing new Mcl-1–targeting agents to overcome therapeutic resistance. 
 

Journal Articles

Tong, J., Zheng, X., Tan, X. Fletcher, R., Nikolovska-Coleska, Z., Yu, J. and Zhang, L. Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins. Cancer Research 78:4704-4715, 2018. 
Knickelbein, K., Tong, J., Chen, D., Wang, Y.J., Misale, S., Bardelli, A., Yu, J. and Zhang, L. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.  Oncogene 37:4599-4610, 2018.
Chen, D., Tong, J., Yang, L., Wei, L., Stolz, D.B., Yu, J., Zhang, J. and Zhang, L.   PUMA amplifies necroptosis signaling by activating cystolic DNA sensors.   Proc. Natl. Acad. Sci. USA 115: 3930-3935, 2018. 
 Tong, J.*, Tan, S.*, Nikolovska-Coleska, Z., Yu, J., Zou, F.*, and Zhang, L*. FBW7-dependent Mcl-1 degradation mediates the anticancer effect of Hsp90 inhibitors. Molecular Cancer Therapeutics 16:1979-1988, 2017.
Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska-Coleska, Z., Zou, F., Yu, J. and Zhang, L. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Research 77:2512-2521, 2017. 
Tong, J., Tan, S., Zou, F., Yu, J. and Zhang, L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 36:787-796,2017.
 
Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, DiNicolantonio F, Nowak MA, Zhang L, Wood KC and Bardelli A.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications 6:8305, 2015.